These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38427314)

  • 21. Particularities of Urinary Tract Infections in Diabetic Patients: A Concise Review.
    Confederat LG; Condurache MI; Alexa RE; Dragostin OM
    Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
    Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
    Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
    J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
    Geerlings S; Fonseca V; Castro-Diaz D; List J; Parikh S
    Diabetes Res Clin Pract; 2014 Mar; 103(3):373-81. PubMed ID: 24529566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
    Arakaki RF
    Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process.
    Pamulapati LG; Rochester-Eyeguokan CD; Pincus KJ
    Am J Health Syst Pharm; 2020 Oct; 77(21):1727-1738. PubMed ID: 32725160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort study.
    Lin YH; Lin CH; Huang YY; Tai AS; Fu SC; Chen ST; Lin SH
    Diabetes Res Clin Pract; 2022 Apr; 186():109816. PubMed ID: 35247527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes.
    Nichols GA; Brodovicz KG; Kimes TM; Déruaz-Luyet A; Bartels DB
    J Diabetes Complications; 2017 Nov; 31(11):1587-1591. PubMed ID: 28888425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study.
    Ferwani P; Maldar A; Shah N; Chauhan P; Chadha M
    J ASEAN Fed Endocr Soc; 2022; 37(2):5-8. PubMed ID: 36578886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-An expert consensus statement.
    Liew A; Lydia A; Matawaran BJ; Susantitaphong P; Tran HTB; Lim LL
    Nephrology (Carlton); 2023 Aug; 28(8):415-424. PubMed ID: 37153973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria].
    Sturov NV; Popov SV; Mamporia NK; Mager AA
    Ter Arkh; 2020 Dec; 92(11):106-109. PubMed ID: 33720614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes.
    Marques LPJ; Mendonça NA; Müller L; André ACPD; Madeira EPQ; Vieira LMSF
    Postgrad Med; 2020 Nov; 132(8):697-701. PubMed ID: 33016178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports.
    Bartolo C; Hall V; Friedman ND; Lanyon C; Fuller A; Morrissey CO; Athan E
    BMC Infect Dis; 2021 Mar; 21(1):284. PubMed ID: 33743624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
    Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
    Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.